The CEO of ActiGraph discusses how these devices are changing patient monitoring in clinical trials.

The latest news for pharma industry insiders.

Industry experts, in a roundtable discussion, explore the evolution of brand engagement in the age of AI, including the growing importance of message relevance—and, for pharma, going where the information is.

Designing an effective travel and lodging patient hub program in pharma.

Dupixent has previously been approved for adults with chronic rhinosinusitis with nasal polyposis whose condition is inadequately controlled.

With competition for follow-on-biologics on the upswing—and a potential market boom perhaps around the corner—continued education and course-setting for all stakeholders in charting the access landscape is paramount.

Study findings indicated that psilocybin can reduce the symptoms of depression, with response and remission rates showing significant support.

Led by Decheng Capital, the successful round of funding also included participation from investors such as Cormorant Asset Management, Surveyor Capital, and the Foundation for Prader-Willi Research.

The latest news for pharma industry insiders.

These factors provide investors with enough information to identify promising investment opportunities.

A greater shift from paper records and physical assets is achievable.

In this Pharmaceutical Executive video interview, Panna Sharma, CEO, Lantern Pharma, discusses how LP-284 uniquely addresses unmet needs compared to existing or emerging treatments for relapsed/refractory lymphomas and solid tumors.

Now-unclear timing on rate cuts puts onus back on fundamentals.

From Big Pharma to biotech—and a globe-spanning journey along the way—Yvonne Greenstreet, this year’s Healthcare Businesswomen’s Association Woman of the Year, is right where she wants to be: leading efforts to advance “bold ideas” in RNAi therapeutics into life-changing gains for patients.

The National Institute for Public Employee Healthcare Policy attributed the importance to the rising cost of health care.

Respondents said they were concerned about their own mental health or the mental health of another person at higher rates since 2022.

The latest news for pharma industry insiders.

The collaboration is a part of a broader strategy to combat cardiometabolic and rare diseases.

In this Pharmaceutical Executive video interview, Panna Sharma, CEO, Lantern Pharma, talks about ensuring global access to LP-284, particularly in regions with limited resources

Strategic financing from Oaktree Capital Management and OMERS Life Sciences is expected to support the US launch of ensifentrine, Verona’s promising chronic obstructive pulmonary disease treatment.

The latest news for pharma industry insiders.

Cencora’s vice president of product management, global products & solutions Beth Riggio discusses the issues the industry faces with recalls and how it can improve.

The new care center will offer primary care services to uninsured and underinsured patients in the Wilmington, North Carolina, area.

In this Pharmaceutical Executive video interview, Panna Sharma, CEO, Lantern Pharma, explains which specific endpoints they'll be looking at in the Phase I trial to assess LP-284's potential efficacy and how the insights gained will be fed back into RADR®